Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome (AVX012CT001)
A Phase I/II, Double-blind, Placebo-controlled Study Assessing the Safety and Efficacy of AVX-012 Ophthalmic Solution in Subjects With Mild-to-moderate Dry Eye Syndrome
Sponsor: Avizorex Pharma, S.L.
A PHASE1/PHASE2 clinical study on Dry Eye Syndrome, this trial is ongoing. The trial is conducted by Avizorex Pharma, S.L. and has accumulated 11 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Nov 2018 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2017 — May 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avizorex Pharma, S.L.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Barcelona, Spain , Granada, Spain , Jerez de la Frontera, Spain , Madrid, Spain , Murcia, Spain , Oviedo, Spain , Pamplona, Spain , Valencia, Spain , Valladolid, Spain and 1 more location